Detection and separation of the anthrapyrazole CI-941 and its metabolites in serum and urine by high-performance liquid chromatography.

[1]  G. Ehninger,et al.  Detection and identification of human urinary metabolites of biantrazole (CI-941). , 1993, Drug metabolism and disposition: the biological fate of chemicals.

[2]  P. Workman,et al.  The impact of pharmacokinetically guided dose escalation strategies in phase I clinical trials: critical evaluation and recommendations for future studies. , 1992, Annals of oncology : official journal of the European Society for Medical Oncology.

[3]  S. Kaye,et al.  Phase I trial of the anthrapyrazole CI-941: prospective evaluation of a pharmacokinetically guided dose-escalation. , 1992, European journal of cancer.

[4]  D. Newell,et al.  Clinical pharmacokinetics of the anthrapyrazole CI-941: factors compromising the implementation of a pharmacokinetically guided dose escalation scheme. , 1992, Cancer research.

[5]  I. Judson,et al.  Anthrapyrazole CI941: a highly active new agent in the treatment of advanced breast cancer. , 1991, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[6]  H. D. Showalter,et al.  Anthrapyrazole anticancer agents. Synthesis and structure-activity relationships against murine leukemias. , 1987, Journal of medicinal chemistry.

[7]  W. Leopold,et al.  Anthrapyrazoles, a new class of intercalating agents with high-level, broad spectrum activity against murine tumors. , 1985, Cancer research.

[8]  H. D. Showalter,et al.  5-[(Aminoalkyl)amino]-substituted anthra[1,9-cd]pyrazol-6(2H)-ones as novel anticancer agents. Synthesis and biological evaluation. , 1984, Journal of medicinal chemistry.